226 related articles for article (PubMed ID: 34287759)
41. Imaging modalities for focal nodular hyperplasia and hepatocellular adenoma.
van den Esschert JW; van Gulik TM; Phoa SS
Dig Surg; 2010; 27(1):46-55. PubMed ID: 20357451
[TBL] [Abstract][Full Text] [Related]
42. Hepatocellular carcinoma and focal nodular hyperplasia in patients with Fontan-associated liver disease: characterisation using dynamic gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid-enhanced MRI.
Shiina Y; Inai K; Sakai R; Tokushige K; Nagao M
Clin Radiol; 2023 Mar; 78(3):e197-e203. PubMed ID: 36481111
[TBL] [Abstract][Full Text] [Related]
43. [Analysis of MRI features of hepatocyte nuclear factor 1α-inactivated hepatocellular adenoma].
Pan H; Chen XF; Han J; Ji Y; Zeng MS; Wang ML
Zhonghua Gan Zang Bing Za Zhi; 2023 Nov; 31(11):1192-1197. PubMed ID: 38238954
[No Abstract] [Full Text] [Related]
44. A Model-Based Prediction of the Probability of Hepatocellular Adenoma and Focal Nodular Hyperplasia Based on Characteristics on Contrast-Enhanced Ultrasound.
Taimr P; Bröker MEE; Dwarkasing RS; Hansen BE; de Knegt RJ; De Man RA; IJzermans JNM
Ultrasound Med Biol; 2017 Oct; 43(10):2144-2150. PubMed ID: 28743375
[TBL] [Abstract][Full Text] [Related]
45. Differentiation of focal nodular hyperplasia and hepatocellular adenoma by contrast-enhanced ultrasound.
Dietrich CF; Schuessler G; Trojan J; Fellbaum C; Ignee A
Br J Radiol; 2005 Aug; 78(932):704-7. PubMed ID: 16046421
[TBL] [Abstract][Full Text] [Related]
46. Focal nodular hyperplasia: hepatobiliary enhancement patterns on gadoxetic-acid contrast-enhanced MRI.
van Kessel CS; de Boer E; ten Kate FJ; Brosens LA; Veldhuis WB; van Leeuwen MS
Abdom Imaging; 2013 Jun; 38(3):490-501. PubMed ID: 22729462
[TBL] [Abstract][Full Text] [Related]
47. Hepatospecific MR contrast agent uptake on hepatobiliary phase can be used as a biomarker of marked β-catenin activation in hepatocellular adenoma.
Reizine E; Ronot M; Ghosn M; Calderaro J; Frulio N; Bioulac-Sage P; Trillaud H; Vilgrain V; Paradis V; Luciani A
Eur Radiol; 2021 May; 31(5):3417-3426. PubMed ID: 33146794
[TBL] [Abstract][Full Text] [Related]
48. Gd-EOB-DTPA-enhanced magnetic resonance imaging features of hepatic hemangioma compared with enhanced computed tomography.
Tateyama A; Fukukura Y; Takumi K; Shindo T; Kumagae Y; Kamimura K; Nakajo M
World J Gastroenterol; 2012 Nov; 18(43):6269-76. PubMed ID: 23180948
[TBL] [Abstract][Full Text] [Related]
49. Added value of Gd-EOB-DTPA-enhanced Hepatobiliary phase MR imaging in evaluation of focal solid hepatic lesions.
Haimerl M; Wächtler M; Platzek I; Müller-Wille R; Niessen C; Hoffstetter P; Schreyer AG; Stroszczynski C; Wiggermann P
BMC Med Imaging; 2013 Dec; 13():41. PubMed ID: 24289722
[TBL] [Abstract][Full Text] [Related]
50. Value of gadoxetic acid-enhanced MRI and diffusion-weighted imaging in the differentiation of hypervascular hyperplastic nodule from small (<3 cm) hypervascular hepatocellular carcinoma in patients with alcoholic liver cirrhosis: A retrospective case-control study.
Kim SS; Kim SH; Song KD; Choi SY; Heo NH
J Magn Reson Imaging; 2020 Jan; 51(1):70-80. PubMed ID: 31062483
[TBL] [Abstract][Full Text] [Related]
51. Diagnostic Value of Gd-EOB-DTPA-MRI for Hepatocellular Adenoma: A Meta-Analysis.
Guo Y; Li W; Xie Z; Zhang Y; Fang Y; Cai W; Hong G
J Cancer; 2017; 8(7):1301-1310. PubMed ID: 28607606
[No Abstract] [Full Text] [Related]
52. Enhancement pattern of hepatocellular adenoma (HCA) on MR imaging performed with Gd-EOB-DTPA versus other Gd-based contrast agents (GBCAs): An intraindividual comparison.
Cannella R; Brancatelli G; Rangaswamy B; Minervini MI; Borhani AA; Furlan A
Eur J Radiol; 2019 Oct; 119():108633. PubMed ID: 31437747
[TBL] [Abstract][Full Text] [Related]
53. [The application value of Gd-EOB-DTPA enhanced MRI based radiomics in the differential diagnosis of iso-or hyperintensity HCC and focal nodular hyperplasia in hepatobiliary phase].
Mao HY; Yu YX; Zhang JY; Zhang T; Fan YF; Hu S; Wang XM; Hu CH
Zhonghua Yi Xue Za Zhi; 2023 Sep; 103(33):2599-2606. PubMed ID: 37650206
[No Abstract] [Full Text] [Related]
54. To assess the quantitative features of focal liver lesions in gadoxetic acid enhanced MRI and to determine whether these features can accurately differentiate benign form malignant lesions.
Rybczynska DN; Markiet KE; Pienkowska JM; Szurowska E; Frydrychowski A
Eur J Radiol; 2024 Feb; 171():111288. PubMed ID: 38194844
[TBL] [Abstract][Full Text] [Related]
55. Novel Strategy for Diagnosis of Focal Nodular Hyperplasia Using Gadolinium Ethoxybenzyl Diethylenetriaminepentaacetic Acid: Enhanced Magnetic Resonance Imaging and Magnetic Resonance Elastography.
Takeda N; Tsuchiya A; Natsui K; Ishii Y; Arao Y; Kimura N; Tominaga K; Takeuchi S; Hayashi K; Takamura M; Terai S
Case Rep Gastroenterol; 2021; 15(2):507-512. PubMed ID: 34616248
[TBL] [Abstract][Full Text] [Related]
56. Enhancement of the liver and pancreas in the hepatic arterial dominant phase: comparison of hepatocyte-specific MRI contrast agents, gadoxetic acid and gadobenate dimeglumine, on 3 and 1.5 Tesla MRI in the same patient.
Kim HJ; Kim BS; Kim MJ; Kim SH; de Campos RO; Hernandes M; Semelka RC
J Magn Reson Imaging; 2013 Apr; 37(4):903-8. PubMed ID: 23065959
[TBL] [Abstract][Full Text] [Related]
57. The use of 18F-fluoromethylcholine PET/CT in differentiating focal nodular hyperplasia from hepatocellular adenoma: a prospective study of diagnostic accuracy.
Bieze M; Bennink RJ; El-Massoudi Y; Phoa SS; Verheij J; Beuers U; van Gulik TM
Nucl Med Commun; 2013 Feb; 34(2):146-54. PubMed ID: 23154640
[TBL] [Abstract][Full Text] [Related]
58. Liver biopsy for diagnosis of presumed benign hepatocellular lesions lacking magnetic resonance imaging diagnostic features of focal nodular hyperplasia.
Sannier A; Cazejust J; Lequoy M; Cervera P; Scatton O; Rosmorduc O; Wendum D
Liver Int; 2016 Nov; 36(11):1668-1676. PubMed ID: 26969817
[TBL] [Abstract][Full Text] [Related]
59. Differentiation of focal nodular hyperplasia from hepatocellular adenomas with low-mechanical-index contrast-enhanced sonography (CEUS): effect of size on diagnostic confidence.
Roche V; Pigneur F; Tselikas L; Roux M; Baranes L; Djabbari M; Costentin C; Calderaro J; Laurent A; Rahmouni A; Luciani A
Eur Radiol; 2015 Jan; 25(1):186-95. PubMed ID: 25120205
[TBL] [Abstract][Full Text] [Related]
60. Characterization of hepatic adenoma and focal nodular hyperplasia with gadoxetic acid.
Mohajer K; Frydrychowicz A; Robbins JB; Loeffler AG; Reed TD; Reeder SB
J Magn Reson Imaging; 2012 Sep; 36(3):686-96. PubMed ID: 22674623
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
